Bethesda, Maryland 20892

  • Breast Cancer


RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. PURPOSE: This laboratory study is looking at tumor tissue samples from women with node-positive breast cancer.

Study summary:

OBJECTIVES: - Determine whether levels of phosphorylated Akt (protein kinase B) are associated with disease-free and/or overall survival in women with node-positive breast cancer treated with doxorubicin hydrochloride and cyclophosphamide or doxorubicin hydrochloride, cyclophosphamide, and paclitaxel on protocol NSABP-B-28. - Compare whether patients with pAkt-negative vs pAkt-positive tumors have a superior disease-free survival with the addition of paclitaxel than those treated with doxorubicin hydrochloride and cyclophosphamide alone. OUTLINE: Tissue microarray sections are analyzed for levels of pAkt by immunohistochemistry. PROJECTED ACCRUAL: A total of 3,060 patients will be accrued for this study within 3 years.


DISEASE CHARACTERISTICS: - Diagnosis of breast cancer - Operable disease - Histologically confirmed positive axillary lymph nodes - Prior enrollment on NSABP-B-28 required - Preserved tumor tissue microarray blocks from the NSABP-B-28 study available - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age - 18 to 78 Sex - Female Menopausal status - Not specified Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - Not specified Renal - Not specified PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified



Primary Contact:

Study Chair
Xiaowei Yang, MD, PhD
National Cancer Institute (NCI)

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

Clinical Trials Office - Warren Grant Magnusen Clinical Center
Phone: 888-NCI-1937

Site Status: Recruiting

Data Source:

Date Processed: November 27, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.